Literature DB >> 17406295

The JAM Test and its daughter P-JAM: simple tests of DNA fragmentation to measure cell death and stasis.

David Usharauli1, Ainhoa Perez-Diez, Polly Matzinger.   

Abstract

Cytotoxic T lymphocytes, and other death-inducing agents, have at least two different ways of killing their targets: drilling holes in the target cell membrane, or triggering the targets to commit suicide. The JAM Test is a method that measures the DNA fragmentation that accompanies cell suicide. We label target cells with radioactive DNA-precursor nucleotides and harvest them onto fiberglass filters, which trap large pieces of DNA but pass smaller fragments of apoptotic cells. As a general measure of apoptosis, the JAM Test described here is faster (can be completed in 4 h [or less if labeling is done the night before]), more quantitative, easier, more sensitive, more flexible and cheaper than most other current assays of apoptosis. The P-JAM, also discussed, additionally allows for assessment of death in cells that don't fragment their DNA, and allows for assays of agents that induce cell stasis rather than death.

Entities:  

Mesh:

Year:  2006        PMID: 17406295     DOI: 10.1038/nprot.2006.107

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  12 in total

1.  Resident peritoneal NK cells.

Authors:  Rosemary Gonzaga; Polly Matzinger; Ainhoa Perez-Diez
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

2.  The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.

Authors:  H Yang; N-H Cho; S-Y Seong
Journal:  Clin Exp Immunol       Date:  2009-07-17       Impact factor: 4.330

3.  CD4 cells can be more efficient at tumor rejection than CD8 cells.

Authors:  Ainhoa Perez-Diez; Nathalie T Joncker; Kyungho Choi; William F N Chan; Colin C Anderson; Olivier Lantz; Polly Matzinger
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

4.  Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.

Authors:  Akemi Kosaka; Takayuki Ohkuri; Maki Ikeura; Gary Kohanbash; Hideho Okada
Journal:  Biochem Biophys Res Commun       Date:  2015-02-10       Impact factor: 3.575

5.  Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads.

Authors:  Pavel Bostik; Jaruda Kobkitjaroen; Weining Tang; Francois Villinger; Lara E Pereira; Dawn M Little; Susan T Stephenson; Mark Bouzyk; Aftab A Ansari
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

6.  Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli.

Authors:  M-Y Bae; N-H Cho; S-Y Seong
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

7.  An assay for macrophage-mediated regulation of endothelial cell proliferation.

Authors:  Aslam Ali Khan; Rajendra S Apte
Journal:  Immunobiology       Date:  2008-09-02       Impact factor: 3.144

8.  A real-time killing assay to follow viral epitope presentation to CD8 T cells.

Authors:  Pauline Gourdain; Julie Boucau; Georgio Kourjian; Nicole Y Lai; Ellen Duong; Sylvie Le Gall
Journal:  J Immunol Methods       Date:  2013-09-20       Impact factor: 2.303

9.  Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.

Authors:  Yanjun Liu; Yibing Peng; Michael Mi; Jose Guevara-Patino; David H Munn; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

10.  Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity.

Authors:  Choong-Gu Lee; Ho-Keun Kwon; Jae Ha Ryu; Sung Jin Kang; Chang-Rok Im; Jae Ii Kim; Sin-Hyeog Im
Journal:  BMC Complement Altern Med       Date:  2010-10-20       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.